<code id='EDF69AA5F0'></code><style id='EDF69AA5F0'></style>
    • <acronym id='EDF69AA5F0'></acronym>
      <center id='EDF69AA5F0'><center id='EDF69AA5F0'><tfoot id='EDF69AA5F0'></tfoot></center><abbr id='EDF69AA5F0'><dir id='EDF69AA5F0'><tfoot id='EDF69AA5F0'></tfoot><noframes id='EDF69AA5F0'>

    • <optgroup id='EDF69AA5F0'><strike id='EDF69AA5F0'><sup id='EDF69AA5F0'></sup></strike><code id='EDF69AA5F0'></code></optgroup>
        1. <b id='EDF69AA5F0'><label id='EDF69AA5F0'><select id='EDF69AA5F0'><dt id='EDF69AA5F0'><span id='EDF69AA5F0'></span></dt></select></label></b><u id='EDF69AA5F0'></u>
          <i id='EDF69AA5F0'><strike id='EDF69AA5F0'><tt id='EDF69AA5F0'><pre id='EDF69AA5F0'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:3643
          Illustration of doctors and researchers using innovative technologies for medicine and healthcare with artificial intelligence. -- health tech coverage from STAT
          Adobe

          At first glance, the Coalition for Health AI looks like any technology lobbying group. Its membership — including Microsoft, Google, and many of the nation’s largest academic hospitals — forms a formidable presence in Washington.

          But on Monday, the coalition forged a different deal with federal regulators. It will work with them to develop quality and safety standards for artificial intelligence, an experiment that will test whether industry and government can effectively partner in the regulation of a fast-moving technology.

          advertisement

          The nonprofit announced that its board of directors will include leaders from the Food and Drug Administration and the Office of the National Coordinator for Health Information Technology — agencies that, until now, have been setting up guardrails for AI in health care on their own. Government staffers will now work alongside industry scientists to develop evaluation methods and address new questions posed by generative AI and its emerging applications.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          The Readout: Gilead, Bernie Sanders, and other pharma news
          The Readout: Gilead, Bernie Sanders, and other pharma news

          YichuanCao/SipaUSAWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechn

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          What should King Charles tell the public about his cancer?

          AphotoillustrationshowingaselectionoffrontpagescoveringthenewsofKingCharlesbeingdiagnosedwithanunspe